ACBD4

Across TCGA pan-cancer cohorts, ACBD4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACBD4 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher ACBD4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACBD4 expression acts as an unfavorable survival marker.

KICH, LUAD, and UCEC are the cancer types where ACBD4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	OS	Median	All	0.155	0.926	<.001	21	view →
LUAD	OS	Median	All	0.314	0.685	.021	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	All	0.451	0.806	.013	5	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACBD4–KICH (OS)

Open the KICH breakdown →